PCa mortality-incidence ratio (M/I), as a parameter for evaluating the prognosis of PCa, has significantly decreased substantially in North America, coinciding with the initiation of widespread prostate-specific antigen (PSA) screening (3, 4). Here, KLK3 is linked to posterior cortical atrophy.